Spyre Therapeutics (SYRE) Other Accumulated Expenses (2015 - 2026)
Spyre Therapeutics (SYRE) posted Other Accumulated Expenses of $165000.0 for Q1 2026, down 7.82% on a QoQ basis from $179000.0 in Q4 2025, and down 55.53% year-over-year from $371000.0 in Q1 2025.
Spyre Therapeutics (SYRE) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $165000.0 for Q1 2026.
- Quarterly Other Accumulated Expenses fell 55.53% year-over-year to $165000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165000.0 (down 55.53% YoY) and the FY2025 annual result came in at $179000.0, down 64.27% from the prior year.
- Other Accumulated Expenses was $165000.0 for Q1 2026 at Spyre Therapeutics, down from $179000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $726000.0 in Q1 2022 and bottomed at $165000.0 in Q1 2026.
- A 5-year average of $361400.0 and a median of $362000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 97.82% — and 2025, when it slumped 67.68%.
- Spyre Therapeutics' Other Accumulated Expenses stood at $330000.0 in 2022, then soared by 47.88% to $488000.0 in 2023, then gained by 2.66% to $501000.0 in 2024, then plunged by 64.27% to $179000.0 in 2025, then retreated by 7.82% to $165000.0 in 2026.
- Business Quant data shows SYRE's Other Accumulated Expenses at $165000.0 in Q1 2026, $179000.0 in Q4 2025, and $170000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,000.00 |
| Dec 31, 2025 | 179,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 242,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 526,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Dec 31, 2023 | 488,000.00 |
| Jun 30, 2023 | 386,000.00 |
| Mar 31, 2023 | 279,000.00 |
| Dec 31, 2022 | 330,000.00 |
| Sep 30, 2022 | 362,000.00 |
| Jun 30, 2022 | 461,000.00 |
| Mar 31, 2022 | 726,000.00 |
| Dec 31, 2021 | 783,000.00 |
| Sep 30, 2021 | 960,000.00 |
| Jun 30, 2021 | 1.13 Mn |
| Mar 31, 2021 | 367,000.00 |
| Dec 31, 2020 | 464,000.00 |